The Lancet's Biggest Prostate Cancer Update in 10 Years Changes Everything

The Lancet just published the most comprehensive update on prostate cancer in a decade — here's what every man needs to know. In this first episode of Journal Club, I review two landmark Lancet publications: the 2024 Commission projecting cases will double to 2.9 million by 2040, and the December 2025 Seminar updating every major diagnostic and treatment pathway. I cover the screening changes that affect you directly, why active surveillance is now the preferred approach for low-risk disease, how PSMA-PET has transformed staging, and the four Commission recommendations that change what you should be asking your doctor. Questions to ask your specialist after watching: • Has my staging included PSMA-PET imaging? • Am I a candidate for active surveillance based on the latest evidence? • What is my individual risk profile — and should I be screened differently? • How does my family history or ethnicity affect my risk? ⏱ TIMESTAMPS 0:00 — What The Lancet just published 0:30 — Why these publications matter 1:15 — The numbers: cases doubling by 2040 3:15 — The plan: four recommendations that affect you 4:45 — Clinical updates: active surveillance, PSMA-PET, treatment advances 6:30 — The verdict: what this means for you 7:30 — Next episode + CTA 📚 REFERENCES The Lancet Commission on prostate cancer: planning for the surge in cases. James ND et al. The Lancet. 2024;403(10437):1683-1722. Prostate cancer (Seminar). The Lancet. December 2025. 🔗 MORE FROM THE PROSTATE CLINIC Website: https://www.prostates.com.au This video represents my opinions only and should not be taken as individual medical advice. Please consult your own doctor or specialist for advice specific to your situation.